乾癬性関節炎患者におけるグセルクマブの長期安全性: 乾癬と乾癬性関節炎を対象とした11つのフェーズ II/III試験の統合解析
Drug Saf 2023;47(1)39–57 doi:10.1007/s40264-023-01361-w
Data gathered from 11 phase 2 and phase 3 trials have shown that guselkumab has a favourable safety profile in treating psoriatic disease. The data were gathered from 4399 patients over 10787 patient years. In the placebo-controlled periods, guselkumab showed a similar safety profile to placebo, and this remained consistent and stable in the non-placebo controlled preiods.